Pazopanib

Source: Wikipedia, the free encyclopedia.
Pazopanib
Clinical data
Pronunciation/pæˈzoʊpənɪb/ paz-OH-pə-nib
Trade namesVotrient
AHFS/Drugs.comMonograph
MedlinePlusa610013
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth (tablets)
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability21% (14–39%)[1]
Protein binding>99.5%[1][2]
MetabolismLiver: CYP3A4 (major), 1A2 and 2C8 (minor)[2]
Elimination half-life30.9±4 hours[1]
ExcretionFaeces (primary), urine (<4%)[2]
Identifiers
  • 5-({4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide
JSmol)
  • O=S(=O)(N)c1c(ccc(c1)Nc2nccc(n2)N(c4ccc3c(nn(c3C)C)c4)C)C
  • InChI=1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H checkY
  • Key:MQHIQUBXFFAOMK-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Pazopanib, sold under the brand name Votrient, is an

soft tissue sarcoma by numerous regulatory administrations worldwide.[3][4][5][6]

Medical uses

It is approved by numerous regulatory administrations worldwide, including the US

Pharmac respectively, under a number of conditions, including:[7][8]

  • The medication is used to treat clear cell renal cell carcinoma, the most common histological subtype.
  • The treatment phase is continuing treatment beyond 3 months.
  • The patient has been issued an authority prescription for pazopanib.
  • The patient must have stable or responding disease according to the Response Evaluation Criteria In Solid Tumours (RECIST).
  • This treatment must be the sole tyrosine kinase inhibitor subsidised for this condition.

Pazopanib has also demonstrated initial therapeutic properties in patients with ovarian and non-small cell lung cancer,[9][unreliable medical source?] though plans to apply to the EMA for a variation to include advanced ovarian cancer have been withdrawn and a license will not be sought in any country.[10][11]

Contraindications

The only contraindication is hypersensitivity to pazopanib or any of its excipients.[5] Cautions include:[2]

It has one black box warning by the US FDA, namely severe hepatotoxicity including fatalities.[2][3]

Adverse effects

See also: List of adverse effects of pazopanib

The most common side effects of pazopanib are nausea, vomiting, diarrhoea (occurs in about half of patients), changes in hair colour, hypertension (which usually occurs during the first few weeks of treatment), appetite loss,

lymphopenia).[12] It has been associated with a low, but real risk of potentially fatal liver damage.[12]

Overdose

The treatment for overdose is purely supportive and the symptoms include grade 3 hypertension and fatigue.[5]

Interactions

Drug interactions include:[2]

Pharmacology

Mechanism of action

Pazopanib is a multiple kinase inhibitor that limits tumor growth by

c-KIT and FGFR.[2][12][15][16][17][18]

Pharmacokinetics

After oral intake of a single tablet, pazopanib has a bioavailability of 21% with a range of 14–39% between people. It reaches highest concentrations in the blood plasma after median 3.5 hours; the range in studies was 1.0 to 11.9 hours. When taken regularly, the area under the curve (AUC) increases 1.23- to 4-fold as compared to a single dose. Taking the drug together with food approximately doubles the AUC as well as the highest plasma concentrations (Cmax); and crushing the tablet increases the AUC 1.46-fold, as well doubling the Cmax.[1][4]

When in the bloodstream, more than 99.5% of the substance are bound to

hydroxyl derivatives and possibly a carboxylic acid. Only 6% of the circulating substance is in the form of metabolites, and all but one of them are 10- to 20-fold less active than pazopanib itself. Consequently, the metabolites are not considered important for the drug's therapeutic effect.[1][4]

Pazopanib is eliminated with a biological half-life of 30.9±4 hours on average (range 21–51 hours) mainly via the faeces. Less than 4% are eliminated via the urine.[1][4]

References

  1. ^ a b c d e f "CHMP Assessment Report: Votrient (pazopanib)" (PDF). European Medicines Agency. Retrieved 8 October 2016.
  2. ^ a b c d e f g h "Votrient (pazopanib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 27 January 2014.
  3. ^ a b c "Votrient- pazopanib hydrochloride tablet, film coated". DailyMed. 17 August 2020. Retrieved 9 November 2020.
  4. ^ a b c d e "Votrient : EPAR - Product Information" (PDF). European Medicines Agency. Glaxo Group Ltd. 23 January 2014. Retrieved 27 January 2014.
  5. ^ a b c d "Votrient 200 mg and 400 mg film coated tablets - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. GlaxoSmithKline UK. 20 December 2013. Retrieved 27 January 2014.
  6. ^ a b "Product Information Votrient Tablets" (PDF). TGA eBusiness Services. GlaxoSmithKline Australia Pty Ltd. 25 March 2013. Retrieved 27 January 2014.
  7. ^ "Pharmaceutical Benefits Scheme (PBS) - Pazopanib". Pharmaceutical Benefits Scheme. Australian Government. Retrieved 27 January 2014.
  8. ^ "Pazopanib - Online Pharmaceutical Schedule". Pharmaceutical Management Agency. Retrieved 9 June 2015.
  9. ^ "Pazopanib shows encouraging activity in several tumour types, including soft tissue sarcoma and ovarian cancer". FierceBiotech. 2008-09-15. Retrieved 2010-08-10.
  10. ^ "GSK pulls bid to extend use of kidney drug to ovarian cancer". Reuters. 31 March 2014. Retrieved 7 April 2014.
  11. ^ "Regulatory update: Votrient (pazopanib) as maintenance therapy for advanced ovarian cancer in the EU". GlaxoSmithKline. 31 March 2014. Archived from the original on 8 April 2014. Retrieved 7 April 2014.
  12. ^
    S2CID 2178331
    .
  13. PMID 24643910
    .
  14. PMID 24807167
    .
  15. S2CID 5063031
    .
  16. S2CID 1738165
    .
  17. PMID 22341567
    .
  18. ^ Rimel BJ (April 2015). "Antiangiogenesis agents in ovarian cancer". Contemporary Oncology. 7 (2): 16–19.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Pazopanib&oldid=1190969778"